Literature DB >> 7024431

Experimental subacute sclerosing panencephalitis: selective disappearance of measles virus matrix protein from the Central nervous system.

K P Johnson, E Norrby, P Swoveland, D R Carrigan.   

Abstract

Subacute sclerosing panencephalitis (SSPE) is caused by a cell-associated or defective form of measles virus. The matrix protein of measles virus may be absent in patients with SSPE which could explain the defective nature of the virus in these patients. In an experimental model of SSPE in hamsters, measles virus in brain tissue is known to convert from a complete infectious form to a cell-associated or defective form eight to 12 days after intracerebral inoculation. Rabbit sera containing antibodies to two individual measles virus polypeptides, the nucleocapsid protein and matrix protein, were used in immunofluorescent and ultrastructural immunoperoxidase studies to label these proteins in brains of hamsters. During the early phase of infection when complete infectious virus could be isolated from brain tissue, both proteins were labeled. However, by 17 days after inoculation, when only cell-associated virus could be rescued from brain tissue, the nucleocapsid protein remained but the matrix protein had disappeared.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7024431     DOI: 10.1093/infdis/144.2.161

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Structural defect linked to nonrandom mutations in the matrix gene of biken strain subacute sclerosing panencephalitis virus defined by cDNA cloning and expression of chimeric genes.

Authors:  M Ayata; A Hirano; T C Wong
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Analysis of the Sendai virus M gene and protein.

Authors:  B M Blumberg; K Rose; M G Simona; L Roux; C Giorgi; D Kolakofsky
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

3.  Reversible repression and activation of measles virus infection in neural cells.

Authors:  C A Miller; D R Carrigan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  Measles virus matrix protein gene expression in a subacute sclerosing panencephalitis patient brain and virus isolate demonstrated by cDNA hybridization and immunocytochemistry.

Authors:  H R Brown; N L Goller; H Thormar; R Rudelli; W W Tourtellotte; P Shapshak; R Boostanfar; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

5.  Measles virus matrix protein detected by immune fluorescence with monoclonal antibodies in the brain of patients with subacute sclerosing panencephalitis.

Authors:  E Norrby; K Kristensson; W J Brzosko; J G Kapsenberg
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

6.  Expression of five viral antigens in cells infected with wild-type and SSPE strains of measles virus: correlation with cytopathic effects and productivity of infections.

Authors:  K P Johnson; E Norrby; P Swoveland; D R Carrigan
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

7.  Fuzzy material surrounding measles virus nucleocapsids identified as matrix protein. Brief report.

Authors:  H R Brown; N Goller; H Thormar; E Norrby
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

8.  Identification of a nonproductive, cell-associated form of measles virus by its resistance to inhibition by recombinant human interferon.

Authors:  D R Carrigan; C M Kabacoff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

9.  Subacute sclerosing panencephalitis: are antigenic changes involved in measles virus persistence?

Authors:  M J Carter; V Ter Meulen
Journal:  Prog Brain Res       Date:  1983       Impact factor: 2.453

10.  Late onset, symptomatic, demyelinating encephalomyelitis in mice infected with MHV-JHM in the presence of maternal antibody.

Authors:  S Perlman; R Schelper; E Bolger; D Ries
Journal:  Microb Pathog       Date:  1987-03       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.